Persistence, Dosing, and Other Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics in United States

BACKGROUND: This study examined biologic persistence, dosing, and other treatment patterns among Crohn’s disease (CD) patients that initiated adalimumab (ADA), certolizumab pegol (CZP), infliximab (IFX), ustekinumab (UST), and vedolizumab (VDZ). METHODS: This descriptive study pooled data from IBM M...

Descripción completa

Detalles Bibliográficos
Autores principales: Teeple, Amanda, Sah, Janvi, Mallampati, Rajesh, Adams, Christopher, Waters, Dexter, Muser, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802353/
https://www.ncbi.nlm.nih.gov/pubmed/36777272
http://dx.doi.org/10.1093/crocol/otab076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802353/
https://www.ncbi.nlm.nih.gov/pubmed/36777272
http://dx.doi.org/10.1093/crocol/otab076

Ejemplares similares